<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05083494</url>
  </required_header>
  <id_info>
    <org_study_id>2020-048</org_study_id>
    <nct_id>NCT05083494</nct_id>
  </id_info>
  <brief_title>Real-time Monitoring of Concentration and Size Variations of Circulating Plasma Free DNA to Predict Early Response to Immunotherapies in Patients With Different Types of Cancer.</brief_title>
  <acronym>SCHISM</acronym>
  <official_title>Real-time Monitoring of Concentration and Size Variations of Circulating Plasma Free DNA to Predict Early Response to Immunotherapies in Patients With Different Types of Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunotherapy, which can be represented by the immune checkpoint blockade, is a milestone in&#xD;
      the progress of the ongoing struggle against cancer. However, the emergence of unexpected&#xD;
      tumor response patterns, such as pseudo-progression or hyper-progression, might complicate&#xD;
      the management of patients receiving these immune checkpoint inhibitors. A reliable&#xD;
      standardized biomarker that can be used in clinical practice for predicting response to&#xD;
      treatment, monitoring tumor evolution and evaluating treatment efficacy has not yet been&#xD;
      established.&#xD;
&#xD;
      The general aim of this study is to assess the interest of the plasmatic free circulating DNA&#xD;
      (cfDNA) on the clinical response for patients with different types of cancer treated with&#xD;
      immunotherapies. The primary objective is to assess the performance of the plasmatic free&#xD;
      circulating DNA using the estimation of the receiver operating characteristic (ROC) curve and&#xD;
      calculation of the area under the curve (AUC) on the response rate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Interest of the plasmatic free circulating DNA (cfDNA)</measure>
    <time_frame>At first evaluation, then 1 administration over 2 for 1 year then at 18 months and an additional sample will be taken at the time of recurrence</time_frame>
    <description>The primary objective is to assess the performance of the plasmatic free circulating DNA using the estimation of the receiver operating characteristic (ROC) curve and calculation of the area under the curve (AUC) on the response rate</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Melanoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>clear cell renal cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Urothelial Carcinoma of the bladder</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>squamous cell carcinomas of the head and neck</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non-small cell lung cancer</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients starting a cancer treatment, as part of marketing treatment (alone or in&#xD;
        combination) in five type of cancer (melanoma, clear cell renal cancer, urothelial&#xD;
        carcinomas of the bladder, squamous cell carcinomas of the head and neck and non-small cell&#xD;
        lung cancer).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients starting anti-PD1 immunotherapy as part of marketing authorization alone or&#xD;
             in combination (melanoma, clear cell renal cancer, urothelial carcinomas of the&#xD;
             bladder, squamous cell carcinomas of the head and neck and non-small cell lung&#xD;
             cancer).&#xD;
&#xD;
          -  No contraindications to immunotherapy&#xD;
&#xD;
          -  Non-pregnant patient&#xD;
&#xD;
          -  Patient not opposed to participation in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV seropositivity&#xD;
&#xD;
          -  Patient with psychiatric or other conditions that may compromise his or her ability to&#xD;
             give non opposition or to follow study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Sebastien Salas, Professor</last_name>
    <phone_ext>+33</phone_ext>
    <email>sebastien.salas@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>APHM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Salas, MD</last_name>
      <email>sebastien.salas@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

